Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09WTQ
|
|||
| Former ID |
DIB010234
|
|||
| Drug Name |
RC-8800
|
|||
| Synonyms |
24-hydroxylase inhibitor (prostate cancer), Rejuvenon; 24-hydroxylase inhibitor (prostate cancer), Sapphire
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [1] | |
| Company |
Novo Nordisk A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholesterol 24-monooxygenase (CYP46A1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022826) | |||
| REF 2 | Clinical pipeline report, company report or official report of Boston Millennia Partners. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.